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ORIGINAL ARTICLE
Background/Aims: Thiazolidinediones reduce urinary albumin excretion and may prevent the development of
renal injury. We evaluated the long-term effects of rosiglitazone on the progression of renal dysfunction in patients
with type 2 diabetes mellitus.
Methods: We enrolled patients with type 2 diabetes mellitus who initially had normal or mildly impaired renal function,
defined as an estimated glomerular filtration rate (eGFR) of 60-120 mL/min per 1.73 m
2, and normoalbuminuria.
Patients were divided into two groups according to their use of rosiglitazone during 3 years of follow-up: those
treated with rosiglitazone (rosiglitazone group, n=52) and those treated without rosiglitazone (control group, n=85).
Progression of renal dysfunction was defined as a decrease in eGFR of ≥9 mL/min per 1.73 m
2 after 3 years.
Results: A greater difference was observed in the decrease in eGFR between the rosiglitazone and control
groups after 3 years (3.8±9.9 vs. 12.6±10.5 mL/min per 1.73 m
2, p<0.001). Seventeen of 52 (32.7%) patients in
the rosiglitazone group and 53 of 85 (62.3%) patients in the control group showed progression of renal
dysfunction (p=0.001). The progressors had a longer duration of diabetes (6.7±5.9 vs. 3.9±4.1 years, p=0.002),
higher HbA1c levels (7.4±1.8 vs. 6.8±1.3%, p=0.023), and less frequent use of rosiglitazone (24.2 vs. 52.2%,
p<0.001) compared to non-progressors. Multiple logistic regression analysis revealed that the use of rosiglitazone
was a significant and independent predictor of the progression of renal dysfunction.
Conclusions: This study suggests that rosiglitazone theatment slows the progressive deterioration of renal
function in patients with type 2 diabetes. (Korean J Intern Med 2009;24:227-232)
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INTRODUCTION
The thiazolidinediones (TZDs), such as rosiglitazone
and pioglitazone, comprise a class of agents that lower
blood glucose through a reduction in insulin resistance in
patients with type 2 diabetes. Apart from improving
glycemic control, several experimental and clinical studies
support the idea that TZDs also have beneficial effects on
the progression of diabetic nephropathy [1-11]. The long-
term effects of TZDs on renal dysfunction are important
because patients often use them as continuous therapy for
a long time. However, most studies on the renoprotective
effects of TZDs in humans have been short term (<1 year),
and the effects are typically only assessed by amelioration
of albuminuria, not changes in renal function.
The American Diabetes Association recommends that
serum creatinine and urinary albumin excretion (UAE) be
measured at least annually in all patients with type 2
diabetes [12]. A substantial percentage of adults with
diabetes have impaired renal function, defined as a
glomerular filtration rate (GFR) <60 mL/minutes per
1.73 m
2, but they also typically show normoalbuminuria
[13,14].  In addition, only 33% of patients with diabetes
who had GFR values of 30-60 mL/minutes per 1.73 m
2had serum creatinine values >120 µmol/L, the upper limit
of normal [15].  This indicates that serum creatinine alone
should not be used as a measure of kidney function, and
that instead, esti-mated GFR should be used, regardless of
the degree of UAE [15].
In the present study, we investigated the long-term
effects of rosiglitazone on renal function in patients with
type 2 diabetes who showed normoalbuminuria and
normal or slightly decreased GFR. 
METHODS
We conducted a retrospective study on patients with
type 2 diabetes who visited the diabetes clinic at St.
Mary’s Hospital, Seoul, Korea, between October 2001
and September 2004 by reviewing their medical records.
Only patients with a UAE <20 µg/minutes and a GFR of
60-120 mL/minutes per 1.73 m
2at baseline were included.
We excluded patients with acute febrile infections, hema-
turia, pyuria, or a positive urine culture, and those who
had been treated with rosiglitazone for less than 3
years. In total, 137 patients met the criteria. Patients
were divided into two groups according to their use of
rosiglitazone for 3 years: those treated with rosiglitazone
(rosiglitazone group, n=52) and those treated without
rosiglitazone (control group, n=85). Serum creatinine
levels and UAE were measured every year.
After an overnight fast, blood samples were obtained
for analysis of serum concentrations of creatinine, total
cholesterol, triglyceride, and HDL cholesterol. Total
cholesterol and triglyceride concentrations were mea-
sured enzymatically. HDL cholesterol concentrations
were measured enzymatically after precipitation of
the other lipoproteins. The HbA1c level was determined
by high-performance liquid chromatography, with a
reference range of 4.4-6.4%. UAE was measured by 24-
hours urine collection. Albumin concentrations were
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Table 1. Patient characteristics
Control Rosiglitazone p value
(n=85) (n=52)
Age, years 54.9±9.7 54.1±9.4 0.660
Male/female 45/40 33/19 0.287
Duration of diabetes, years 5.4±5.5 5.2±4.9 0.813
BMI, kg/m
2 24.5±3.2 23.4±2.7 0.063
Serum creatinine, µmol/L  75.5±11.7 83.6±13.1 <0.001
eGFR, mL/min per 1.73 m
2 88.5±13.4 81.2±10.6 0.001
Use of ACE inhibitor or ARB 36 14 0.099
Use of statin 6 9 0.089
Use of insulin 15 3 0.066
At baseline
Systolic blood pressure, mmHg 129.2±15.3 123.6±12.9 0.029
Diastolic blood pressure, mmHg 77.9±10.8 75.3±9.9 0.165
HbA1c, % 7.4±1.6 6.8±1.5 0.046
Total cholesterol, mmol/L 5.0±1.0 4.7±0.7 0.067
Triglyceride, mmol/L 1.6±0.9 1.4±0.7 0.269
HDL cholesterol, mmol/L 1.0±0.2 1.1±0.3 0.449
After 3 years
Systolic blood pressure, mmHg 128.9±15.8 124.8±12.3 0.117
Diastolic blood pressure, mmHg 77.2±9.8 74.3±8.6 0.084
HbA1c, % 7.1±1.2 6.8±1.3 0.161
Total cholesterol, mmol/L 4.6±0.9 4.3±0.8 0.123
Triglyceride, mmol/L 1.5±0.8 1.2±0.7 0.083
HDL cholesterol, mmol/L 1.1±0.3 1.3±0.3 0.054
Values are mean±SD or number.
BMI, body mass index; eGFR, estimated glomerular filtration rate; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor
blocker; HbA1c, glycosylated hemoglobin; HDL, high density lipoprotein.deter-mined by immunoturbidimetry (Alb-Tia Seiken;
Denka Seiken, Tokyo, Japan).
GFR was calculated using the Modification of Diet in
Renal Disease (MDRD) formula: 
estimated GFR (eGFR)=186.3×[SCr×0.011]
-1.154×age
-0.203
[×0.742, if female],
where SCr is serum creatinine expressed in µmol/L.
Because of concerns about the validity of the MDRD
equation for subjects with higher levels of kidney function
and glomerular hyperfiltration in patients with early
diabetes, subjects with baseline GFR values exceeding
120 mL/minutes per 1.73 m
2 were also excluded [16].
Progression of renal dysfunction was defined as a decrease
in the eGFR of ≥9 mL/minutes per 1.73 m
2 after 3 years,
as proposed by Klein et al. [17]. Renal function was graded
according to the Kidney Disease Outcomes Quality
Initiative guidelines [18]: stage 1, ≥90; stage 2, 60-89;
stage 3, 30-59; stage 4, 15-29; and stage 5, <15 mL/min
per 1.73 m
2.
Statistical analyses were performed using the SPSS
statistical package (SPSS Inc., Chicago, IL, USA). Because
triglyceride values are not normally distributed, the data
were analyzed after logarithmic transformation. Differences
in continuous variables between the groups were ana-
lyzed by Student’s t-test. The χ
2 test was used to compare
frequencies between the two groups. The correlation
between the decrease of eGFR after 3 years and other
variables in the study subjects was examined by Pearson
correlation analysis. Multiple logistic regression was
performed to assess the independent predictive effect of
the variables on the risk for progression of renal
dysfunction. P values <0.05 were deemed to be statistically
significant. 
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Table 2. Clinical and biochemical characteristics of progressors and non-progressors
Progressors Non-progressors p value
(n=70) (n=67)
Decrease in eGFR, mL/min per 1.73 m
2 18.2±6.4 0.0±6.1 <0.001
Age, years 55.3±9.8 53.9±9.3 0.425
Male/female 38/32 40/27 0.605
Duration of diabetes, years 6.7±5.9 3.9±4.1 0.002
BMI, kg/m
2 24.5±2.8 23.7±3.3 0.190
Use of rosiglitazone  17 35 0.001
Use of ACE inhibitor or ARB  29 21 0.287
Use of statin 6 9 0.420
Use of insulin 13 5 0.076
At baseline
Systolic blood pressure, mmHg 127.2±15.5 126.9±13.8 0.908
Diastolic blood pressure, mmHg 77.9±11.4 75.9±9.6 0.265
HbA1c, % 7.4±1.8 6.8±1.3 0.023
Total cholesterol, mmol/L 4.9±0.9 4.8±0.9 0.259
Triglycerides, mmol/L  1.7±0.9 1.5±0.7 0.201
HDL cholesterol, mmol/L  1.0±0.2 1.1±0.2 0.687 
After 3 years
Systolic blood pressure, mmHg 129.0±16.2 125.6±12.7 0.179
Diastolic blood pressure, mmHg 75.6±9.1 76.7±9.8 0.490
HbA1c, % 7.2±1.3 6.8±1.1 0.044
Total cholesterol, mmol/L 4.5±0.9 4.4±0.8 0.426
Triglyceride, mmol/L 1.4±0.8 1.4±0.8 0.748
HDL cholesterol, mmol/L  1.1±0.3 1.2±0.3 0.134
Values are mean±SD or number.
eGFR, estimated glomerular filtration rate; BMI, body mass index; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor
blocker; HbA1c, glycosylated hemoglobin; HDL, high density lipoprotein.RESULTS
The clinical characteristics of the study subjects at
baseline are summarized in Table 1. The control and
rosiglitazone groups showed no significant difference in
age, gender, BMI, duration of diabetes, use of an ACE
inhibitor or an angiotensin II receptor blocker (ARB),
statin use, or insulin use. Systolic blood pressure and
HbA1c were lower in the rosiglitazone group than in the
control group. The rosiglitazone group had higher serum
creatinine levels and lower eGFR values than the control
group. After 3 years, no significant difference in blood
pressure, HbA1c, or lipid profiles was observed between
the control and rosiglitazone groups (Table 1).
The median decrease in eGFR after 3 years in all subjects
was 9.8 mL/minutes per 1.73 m
2. The decrease in eGFR
was not different between the two groups after 1 year
(0.0±9.7 vs 2.8±11.4 mL/minutes per 1.73 m
2, p=0.167).
However, the decrease in eGFR was significantly less in
the rosiglitazone group than in the control group after 2
years (2.5±9.5 vs. 6.9±11.4 mL/minutes per 1.73 m
2,
p=0.046) and 3 years (3.8 ±9.9 vs 12.6±10.5 mL/minutes
per 1.73 m
2, p<0.001, Fig. 1). As a result, the eGFR was
similar after 3 years between the two groups (75.8±13.6
vs 76.8±11.1 mL/minutes per 1.73 m
2, p=0.655), although
it was higher at baseline in the control group than in the
rosiglitazone group (88.5±13.4 vs 81.2±10.6 mL/minutes
per 1.73 m
2, p<0.001).
Seventy subjects experienced a progression in renal
dysfunction (‘progressors’) after 3 years. Clinical and
biochemical characteristics of progressors and non-
progressors at baseline and after 3 years are shown in
Table 2. The two groups did not differ significantly in
age, gender, BMI, use of ACE inhibitors or ARBs, blood
pressure, or lipid profiles. The progressors had a longer
duration of diabetes (6.7±5.9 vs. 3.9±4.1 years, p=0.002),
higher HbA1c levels (7.4±1.8 vs. 6.8±1.3%, p=0.023 at
baseline; 7.2±1.3 vs. 6.8±1.1%, p=0.044 after 3 years),
and less frequent use of rosiglitazone (24.2 vs. 52.2%,
p<0.001) compared to the non-progressors. More impor-
tantly, 17 of 52 (32.7%) patients in the rosiglitazone group
and 53 of 85 (62.3%) patients in the control group
showed progression of renal dysfunction, as defined by a
decrease in eGFR ≥9 mL/minutes per 1.73 m
2 (p=0.001).
During the study period, 46 of 137 subjects (33.5%)
showed deterioration to a more advanced stage of renal
impairment, as defined by the Kidney Disease Outcomes
Quality Initiative guidelines [18]. Ten of 52 patients
deteriorated to a more advanced stage of renal impair-
ment in the rosiglitazone group compared to 36 of 85
patients in the control group (19.2 vs. 42.3%, p=0.006).
Additionally, 18 patients showed progression to microal-
buminuria (a UAE of 20-200 µg/minutes): 3 of 52
patients in the rosiglitazone group and 15 of 85 patients
in the control group (5.7 vs. 17.6%, p=0.046).
Multiple logistic regression analysis was used to
identify independent predictors of the progression of
renal function. Use of rosiglitazone, baseline eGFR, and
duration of diabetes were all significant and indepen-
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Table 3. Multiple logistic regression analysis of risk factors influencing progression of renal dysfunction
Predictors Odds ratio 95% CI p value
Use of rosiglitazone 0.418 0.181-0.963 0.041
Baseline eGFR, per 20 mL/min per 1.73 m
2 2.410 1.257-4.620 0.008
Duration of diabetes, per 5 years 1.940 1.235-3.049 0.004
Baseline HbA1c, per 2% 1.535 0.936-2.517 0.090
Use of ACE inhibitor or ARB 0.760 0.325-1.779 0.527
Baseline SBP, per 20 mmHg 0.883 0.533-1.464 0.631
CI, confidence interval; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin; ACE, angiotensin converting
enzyme; ARB, angiotensin II receptor blocker; SBP, systolic blood pressure.
Figure 1. Comparison of the decrease in eGFR between control
and rosiglitazone group during the follow-up period. The empty
and closed circles represent the control group and rosiglitazone
group, respectively. A bar indicates the mean value. *p<0.001 vs.
the control group. eGFR, estimated glomerular filtration rate.
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DISCUSSION
This 3-year-old longitudinal study provides the first
evidence that rosiglitazone can slow the progressive
decline in renal function in patients having type 2 diabetes
with normoalbuminuria and normal or slightly decreased
GFR. This association was independent of initial renal
function, ACE inhibition, glycemic control, or duration of
diabetes. 
Many studies have suggested that TZDs reduce urinary
albumin or protein excretion and protect against injury
to the kidney. Studies in animal models [1,2] suggest that
TZDs can prevent diabetic nephropathy, and reduction in
microalbuminuria has been demonstrated in patients
having type 2 diabetes with all TZDs (troglitazone, piogli-
tazone, rosiglitazone) examined [3-11]. However, most of
the studies on the renal effects of rosiglitazone have been
limited by the short duration of follow-up, typically
terminated within 12 months of treatment onset. Bakris
et al. [4] examined the effects of rosiglitazone on UAE in a
52 weeks, open-label, cardiac safety study comparing
rosiglitazone and glyburide. After 28 weeks of treatment,
both groups had significant reductions (about 30%) in
UAE, but after 52 weeks, only the rosiglitazone group
continued to demonstrate a significant reduction in UAE.
Thus, the duration of follow-up is an important variable in
assessing the effects of rosiglitazone. In particular, the
long-term effects of rosiglitazone on renal dysfunction
are of interest because patients often use the drug as a
continuous therapy. To our knowledge, however, no
published study has examined the effects of TZDs on the
progression of kidney disease. Thus, we sought to analyze
the effects of rosiglitazone on long-term changes in renal
function, assessed by eGFR, not UAE, in patients having
type 2 diabetes with normoalbuminuria and normal or
slightly decreased GFR.
First, we demonstrated that the rosiglitazone group
showed slower deterioration of renal function, as assessed
by the decrease in eGFR, over 3 years (3.8 mL/minutes per
1.73 m
2 in the rosiglitazone group vs. 12.6 mL/minutes
per 1.73 m
2 in the control group). Second, fewer patients
in the rosiglitazone group developed microalbuminuria
during the follow-up period (5.7% in the rosiglitazone group
vs. 17.6% in the control group), despite similar numbers of
patients receiving ACE inhibitors or ARBs in each group.
Third, 42.3% of the patients in the control group transitioned
to a more advanced stage of renal dysfunction compared
to 19.2% of those in the rosiglitazone group. Finally, the
progressors who had a decrease in estimated GFR ≥9
mL/minutes per 1.73 m
2 over 3 years had a longer duration
of diabetes, higher HbA1c levels, and less use of rosiglitazone
than the non-progressors. More than half of the non-
progressors (35/67) were taking rosiglitazone. After
adjusting for initial eGFR, duration of diabetes, HbA1c,
and use of an ACE inhibitor/ARB, the use of rosiglitazone
remained an independent predictor of renal outcome.
Thus, the use of rosiglitazone was independently related
to slowing the progression of renal dysfunction in our
subjects, independent of initial renal function, ACE
inhibition, hyperglycemia, and duration of diabetes.
Because patients in the present study had normo-
albuminuria, with normal or mildly decreased GFR, the
possibility exists that the renoprotective effects of rosigli-
tazone could have occurred at earlier stages of kidney
disease.
The mechanisms through which TZDs reduce UAE and
renal injury are unclear [19]. Several systemic actions of
TZDs, such as reductions in blood glucose and insulin, as
well as BP levels, could be involved in the renoprotective
action of these compounds. TZDs initiate their action by
binding to peroxisome proliferators-activated receptor-γ
(PPARγ). Although PPARγ receptors are most abundant
in fat cells, they have also been demonstrated in renal
mesangium and glomerulus. Transforming growth factor
-β (TGF-β) has been recognized as a central player in the
fibrogenic process of diabetic nephropathy, through both
stimulatory effects on matrix production and blocking of
matrix degradation [20]. TZDs suppress the renal
expression of TGF-β reduce urinary albumin excretion,
and ameliorate glomerular injury [21,22].  Miyazaki et al.
[7] reported that decreased albuminuria by rosiglitazone
treatment in patients with type 2 diabetes was indepen-
dently associated with a decrease in TNF-α and an
increase in adiponectin. Thus, TZDs may exert their reno-
protective actions either directly by acting on renal PPARγ
receptors or indirectly by altering adipocytokines released
from fat cells. 
This study was limited by its retrospective design.
Patients in the rosiglitazone group had significantly lower
systolic blood pressures and HbA1c values at the start of
followup. Because these variables are key predictors of the
development and progression of diabetic nephropathy, we
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multiple regression analysis. The study was also limited
by the imperfect method of estimating renal function.
The MDRD equation may underestimate GFR in subjects
with normal renal function, especially those with a GFR
≥90 mL/minutes per 1.73 m
2 [2,23]. However, the primary
interest in our study was in the changes in kidney function,
and such concerns were deemed relatively unimportant. 
In conclusion, our data suggest that TZDs slow the
progressive deterioration of renal function in patients with
type 2 diabetes. However, long-term prospective studies
are required to confirm the findings, especially in patients
with overt proteinuria or renal insufficiency.
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